Phaseline

Companies › Napo Pharmaceuticals

Napo Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Crofelemer
Cystic fibrosis transmembrane conductance regulator inhibitor; Anoctamin-1 blocker
CFTR, ANO1Phase 2Microvillus Inclusion DiseaseDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06721871CrofelemerPhase 2Microvillus Inclusion DiseaseOtherDec 2026

Targets

CFTR (1) ANO1 (1)

Companies with the same targets

Vertex Pharmaceuticals Napo Therapeutics 4D Molecular Therapeutics ReCode Therapeutics Qanatpharma Krystal Biotech Boehringer Ingelheim Arcturus Therapeutics

Companies built like this

Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical Dendrogenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.